J&J wins FDA approval for multiple myeloma drug combo
Tecvayli and Darzalex Faspro combination cleared after demonstrating strong Phase 3 survival data
Johnson & Johnson received regulatory approval for its combination therapy treating multiple myeloma, bolstering the healthcare conglomerate's oncology portfolio in one of the pharmaceutical industry's most competitive disease areas.
The US Food and Drug Administration cleared the use of Tecvayli in combination with Darzalex Faspro for patients with relapsed or refractory multiple myeloma, following strong Phase 3 survival results. The approval provides physicians with a new treatment option for a blood cancer that affects more than 35,000 Americans annually, according to American Cancer Society estimates.
The decision comes at a critical juncture for Johnson & Johnson, the $595 billion pharmaceutical giant that maintains one of only two AAA credit ratings held by US corporations. The company's shares, currently trading at $239.63, have gained significant ground this year, sitting above both the 50-day moving average of $224.59 and the 200-day average of $188.38. The stock is down 2.3% in Thursday's session, retreating from a recent 52-week high of $251.71 reached earlier this month.
Multiple myeloma represents a substantial commercial opportunity for pharmaceutical companies, with the global market for myeloma treatments projected to exceed $30 billion by 2027. J&J's Darzalex franchise has been a cornerstone of the company's oncology business, generating billions in annual sales. The addition of Tecvayli, a bispecific antibody therapy, aims to expand treatment options for patients who have exhausted other therapies.
The company's financial position remains robust, with trailing twelve-month revenue of $94.2 billion and a profit margin of 28.5%. Johnson & Johnson reported quarterly earnings growth of 48.6% year-over-year, alongside revenue growth of 9.1%, demonstrating strong operational momentum despite broader healthcare sector challenges. The company pays a quarterly dividend of $5.14 per share, yielding 2.1% at current prices.
Wall Street analysts maintain a cautiously optimistic outlook on the stock. Of 25 analysts covering the company, 14 rate it a buy or strong buy, while 10 recommend hold positions. The consensus target price of $234.21 suggests modest upside from current levels, though this estimate predates the FDA approval announcement. One analyst maintains a strong sell rating.
The approval strengthens J&J's position in the competitive multiple myeloma market, where the company faces competition from Bristol Myers Squibb, GlaxoSmithKline, and Novartis, among others. The bispecific antibody class, which includes Tecvayli, represents a newer approach to cancer treatment that simultaneously targets two different antigens, potentially improving efficacy while reducing side effects compared to traditional therapies.
Institutional investors hold approximately 75.7% of J&J's outstanding shares, reflecting the company's status as a core holding in many large-cap healthcare portfolios. The stock's beta of 0.33 indicates lower volatility compared to the broader market, consistent with its reputation as a defensive healthcare name.
The FDA decision marks another milestone for J&J's pharmaceutical division, which has been navigating significant corporate changes including the planned spinoff of its consumer health unit, Kenvue. The oncology portfolio has become increasingly important to the company's growth strategy as medical device sales face pressure from hospital cost-cutting measures and supply chain disruptions.
Looking ahead, investors will be monitoring early adoption rates of the Tecvayli-Darzalex Faspro combination, as well as potential competitive responses from rival pharmaceutical companies. Multiple myeloma treatments typically command premium pricing, and the success of this combination therapy could materially impact J&J's pharmaceutical revenue in coming quarters. The company's next quarterly earnings report will provide insight into management's commercialization strategy and market expectations for the newly approved treatment regimen.